INTRODUCTION: In @entity1 with non-metastatic @entity150 ( @entity150 ) fit for curative therapy, a multidisciplinary approach consisting is recommended. This approach includes local treatment (usually radical cystectomy), ideally combined with neoadjuvant chemotherapy (NACT). Despite a survival benefit with NACT, uptake remains low. We assessed NACT consultation in Alberta and examined associative factors, as well as the relationship to survival. METHODS: @entity1 with @entity150 were identified through the Alberta Cancer Registry. Demographic and clinicopathologic information was collected from electronic medical records between 2007 and 2011. In addition to descriptive statistics, logistic regression was used to determine factors associated with receiving NACT consultation. Overall survival was described using a Kaplan-Meier estimate. RESULTS: Of the 315 radical cystectomy @entity1 , 140 (45.1%, 95% confidence interval [CI] 39.5, 50.8) received NACT consultation. @entity1 >= 80 years (odds ratio [OR] 0.21, 95% CI 0.08, 0.57, p = 0.002) and those treated in Calgary (OR 0.11, 95% CI 0.05, 0.25, p < 0.001) were less likely to receive NACT consultation. The rate of NACT consultation increased steadily from 2007 to 2011 (OR 1.23, 95% CI 1.04, 1.45 per year of diagnosis, p = 0.018). After a median follow-up of 28.1 months (range: 14.6-50.3), median survival was 54.7 months for @entity1 who received NACT consultation versus 31.2 months for those who did not (p = 0.030). CONCLUSIONS: NACT consultation in @entity1 with @entity150 undergoing radical cystectomy has improved over time; however, regional differences underscore the need for a standardized approach to NACT consultation, including common referral mechanisms.

Predictors of referral for neoadjuvant chemotherapy prior to radical cystectomy for XXXX and changes in practice over time.

@entity1 :: ('9606', 'Species') :: ['patients', 'Patients'] @entity150 :: ('MESH:D001749', 'Disease') :: ['MIBC', 'muscle-invasive bladder cancer']
@entity150 :: (MESH:D001749,Disease) :: ['muscle-invasive bladder cancer']
